Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 Inhibitor, as Monotherapy and in Combination With Other Agents, in Participants With Haematologic Neoplasms

NCT07064122 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07064122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07064122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 Inhibitor, as Monotherapy and in Combination With Other Agents, in Participants With Haematologic Neoplasms
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
November 3, 2025
Completion date
October 20, 2028
Enrollment
72 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

haematologic neoplasms